Esperion eyes new commercial push for cholesterol-lowering drugs after big FDA label expansion

Es­pe­ri­on has se­cured ma­jor FDA la­bel ex­pan­sions for its two cho­les­terol-low­er­ing drugs, a reg­u­la­to­ry mile­stone that it says opens up a much big­ger mar­ket and “sig­nif­i­cant­ly re­duces pre­vi­ous­ly ex­ist­ing pre­scrib­ing lim­i­ta­tions.”

Nexle­tol and Nexl­izet are now ap­proved to pre­vent heart at­tacks and car­dio­vas­cu­lar pro­ce­dures in both pri­ma­ry and sec­ondary pre­ven­tion pa­tients, re­gard­less of statin use. Both pills con­tain be­mpe­doic acid, Es­pe­ri­on’s key as­set, with one be­ing a monother­a­py and the oth­er be­ing a com­bi­na­tion with an­oth­er cho­les­terol-low­er­ing drug, eze­tim­ibe.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.